15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering CytomX Therapeutics Inc, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $7.00 to $16.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $12.22 sits 280% above the current $3.22. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.49 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Strong Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to CytomX Therapeutics Inc.
As of Jul, 8 of 8 firms rate CTMX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CTMX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.14 – $-0.07 · 6 analysts · +17% YoY
Next period, 6 analysts expect CytomX Therapeutics Inc to earn $-0.11 a share (range $-0.14 – $-0.07), versus $-0.09 a year earlier. Full-year consensus is $-0.42, growing to $-0.49 the year after.
REVENUE · NEXT QUARTER
$6.2M
Range $0 – $12.0M · 6 analysts · +3% YoY
Revenue is expected to reach $6.2M (range $0 – $12.0M), +3.4% year-over-year. Full-year consensus is $35.7M, rising to $34.3M next year.
Top analysts covering CytomX Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTMX.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$15.00+365.8% to target
Overall win rate
55%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #62
Buy
$12.00+272.7% to target
Overall win rate
46%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$11.00+241.6% to target
Overall win rate
34%
+ Follow
#4
Joseph Catanzaro
Piper Sandler · Rank #219
Buy
$12.00+272.7% to target
Overall win rate
41%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$12.00+272.7% to target
Overall win rate
29%
+ Follow
CTMX stock forecast FAQ
What is CTMX's average 12-month price target?+
The 9 analysts with a live target average $12.22 for CytomX Therapeutics Inc over the next 12 months, ranging from a $16.00 high to a $7.00 low.
Is CTMX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CTMX?+
The Street-high target is $16.00 (Barclays), and the Street-low is $7.00 (Oppenheimer). The average of all 9 active targets is $12.22.
How many Wall Street analysts cover CTMX?+
9 analysts have an active rating on CytomX Therapeutics Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering CTMX?+
Among analysts who currently cover CTMX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $15.00 target.
What is CytomX Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.14 – $-0.07) across 6 analysts. Full-year EPS is projected at $-0.42, rising to $-0.49 the following year.
How much revenue is CytomX Therapeutics Inc expected to report next quarter?+
Consensus revenue is $6.2M (range $0 – $12.0M). Full-year revenue is projected at $35.7M, growing to $34.3M next year.
Have analysts been upgrading or downgrading CTMX lately?+
As of Jul, 8 of 8 firms rate CTMX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTMX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
